APPIA BIO

Innovating Cell Therapy

 

TEAM

We collaborate across a diversity of disciplines, which is critical to developing next-generation therapies for patients.

 

OUR TECHNOLOGY

Our research and development efforts are focused on creating engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases therapeutic options and availability for patients. With our ACUA technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Pipetting Samples and Test Tube
 
Image by Nate Bell

MEDIA & PRESS UPDATES

 

APPIA BIO LAUNCHES WITH $52 MILLION SERIES A FINANCING AND ESTABLISHES SCIENTIFIC ADVISORY BOARD

May 11, 2021

GET IN TOUCH

We’re a growing early-stage biotechnology company. We're looking for talented people who are passionate about innovating new medicines at the cutting-edge of science. See our job listings at: 
https://www.linkedin.com/company/appiabio/jobs/

570 Westwood Plaza
Los Angeles, CA